Masking High Protein Drinks Blog Header

Masking Off-Notes in High Protein Drinks

Masking Off-Notes in High Protein Drinks: The Efficacy of Icon Foods’ MonkSweet™ LS4 Monk Fruit Extract and Steviol Glycosides in Concertby Thom King, Icon Foods, Chief Innovations Officer/Food Scientist High-protein ready-to-drink (RTD) beverages represent one of the fastest-growing segments in the functional food and performance nutrition landscape. Consumers ranging from Read more…

Formulating Gut-Healthy Carbonated Drinks

Formulating a Gut-Healthy Carbonated Soft Drink: A Functional Approach for Food Technologists and Beverage Formulatorsby Thom King, Icon Foods, Chief Innovations Officer/Food Scientist Move over protein shakes and IPA-fueled kombucha experiments—there’s a new sheriff in town, and he’s packing bubbles, fiber, and just enough monk fruit to make your taste Read more…

Icon Foods Sweet Success with IconiSweet Gold

Sweet Success with IconiSweet Gold

Sweet Success with IconiSweet Gold By Thom King – Chief Innovations Officer Icon Foods Icon Foods’ IconiSweet Gold is a revolutionary clean-label brown sugar substitute that offers a guilt-free sweetening solution without compromising on taste or texture. This innovative sweetening system contains natural compounds with no added sugar, making it Read more…

Icon Foods ShellBe Candies Blowout Sale

ShellBe Candies Blowout Sale!

ShellBe Candies Blowout Sale! We are liquidating our ShellBe Candies’ stock! These zero sugar added, candy-coated morsels are ideal for formulators looking to add color, flavor, and texture to a wide variety of applications. Don’t miss out—take advantage of these low costs and secure your inventory before our current stock is gone! Read more…

Icon Foods Consumer Demand for Products Containing Soluble Fibers

Consumer Demand for Products Containing Soluble Fibers

Consumer Demand for Products Containing Soluble Fibers By Thom King – Chief Innovations Officer Icon Foods Consumer demand for products containing soluble fibers particularly amongst users of GLP-1 agonists, a class of medications commonly prescribed for individuals suffering from diabesity, is estimated to grow by USD 2.11 billion from 2024-2028, Read more…